CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- 4 Grant or award Chief Commercial Officer acquired 26,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 28,000 shares (grant or award)
- 4 Grant or award VP, Controller acquired 9,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 26,000 shares (grant or award)
- 4 Grant or award CEO and President acquired 87,000 shares (grant or award)
- 4 Grant or award Chf Scientific Operations Off acquired 30,000 shares (grant or award)
- 4 Gift CEO and President gave 300,000 shares (gift)
- 4 Gift CEO and President gave 18,667 shares (gift)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Commercial Officer acquired 50,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4/A Open-market buy Director bought 20,000 shares at $3.19 ($63,800)
- 4 Open-market buy Director bought 20,000 shares at $3.19 ($63,800)
Page 2 of 20 · 382 filings